Previous research suggested that BTKis ibrutinib can largely increase CYLD miRNA transcription, which means increasing CYLD activity, could inhibit cells proliferation in CLL [25]. This evidence concerns the gene CYLD and B-cell chronic lymphocytic leukemia.